Skip to main content

Advertisement

Table 4 non BRCA1/2 mutation group and IHC tumour characteristics.

From: Selecting for BRCA1 testing using a combination of homogeneous selection criteria and immunohistochemical characteristics of breast cancers

ID pts Age at diagnosis Grade ° ER (score) ° PR (score) §HER2 ^ BRCAPRO BRCA1 ^ BRCAPRO BRCA2 ^ BRCAPRO total *BC, CBC and BBC cases *OC cases
BR271 40 G2 + (7) + (5) 1+/2+ 0.002 0.036 0.038 1 (37) /
BR275 28 BBC G3 + (7) + (7) - 0.067 0.578 0.645 1 (55) /
BR281 42 G3 + (6) + (4) 3+ 0.008 0.222 0.230 6 (27, 36, 50, 60, 50 BBC, 60) /
BR297 54 G3 - (0) - (0) - 0.064 0.018 0.081 2 (42, 69) /
BR304 41 G3 + (7) + (6) - 0.002 0.058 0.060 2 (52, 64) /
BR315 46 BBC G2 + (7) + (7) 1+ 0.012 0.160 0.172 1 (49) /
BR335 64 G2 + (8) - (0) 1+ 0.002 0.017 0.020 2 (57, 70) 1 (69)
BR338 36 G3 - (0) - (0) 3+ 0.131 0.029 0.160 2 (45, 71) /
BR339 74 G2 + (7) + (7) - 0.003 0.085 0.088 3 (39, 61+63 CBC, 66) 2 (54, 64)
BR340 35 G3 + (7) - (0) 3+ 0.009 0.026 0.035 2 (43, 59) /
BR348 55 G3 + (7) - (0) 1+ 0.009 0.062 0.071 2 (56, 56) 1 (68)
BR350 42 G3 + (7) + (7) 2+ 0.001 0.014 0.015 4 (49, 57, 61*, 70*) /
BR357 35 G3 + (6) - (0) - 0.002 0.014 0.016 2 (55, 67) /
BR377 46 G3 + (7) + (6) - 0.000 0.007 0.007 2 (46, 70) /
BR380 30 G2 - (0) - (0) 1+/2+ 0.303 0.067 0.370 3 (42, 64, 64) /
BR381 45 G3 + (5) + (6) - 0.000 0.004 0.004 2 (45, 85) /
BR398 50 G2 + (5) + (3) - 0.000 0.020 0.020 5 (60, 61, 65, 70, 98) /
BR403 53+57 CBC G3 + (7) + (7) - 0.000 0.006 0.007 1 (82+84 CBC) /
BR408 53 G2 + (6) + (4) - 0.000 0.002 0.002 3 (71*, 85*, 67°) /
BR414 60 G2 - (2) + (4) - 0.003 0.101 0.104 2 (73M, 50) /
BR418 27 G3 - (0) - (0) 3+ 0.093 0.015 0.108 / /
BR422 55 G3 + (6) - (2) - 0.002 0.014 0.016 2 (50, 53) /
BR424 45 G2 + (5) + (7) 2+ 0.006 0.113 0.119 1 (49+59 CBC) /
BR425 27 G2 + (3) + (5) 3+ 0.001 0.012 0.013 / /
BR439 52 G3 - (0) - (2) - 0.052 0.030 0.082 3 (36, 60, 70) 1 (78)
BR445 54 G1 + (6) + (3) 1+ 0.004 0.067 0.072 2 (45, 48+52 CBC) /
BR446 50 G2 + (7) + (4) 1+ 0.000 0.008 0.008 1 (40) /
BR447 65 G2 + (8) + (6) - 0.001 0.045 0.046 2 (58, 79) /
BR449 50 G2 + (6) + (7) - 0.001 0.020 0.021 1 (37) /
BR457 53 G3 + (4) - (2) 3+ 0.000 0.003 0.004 2 (55, 55) /
BR463 48 G3 + (6) + (5) - 0.001 0.032 0.033 1 (67 BBC) /
BR480 53 G2 + (7) + (7) - 0.004 0.135 0.139 3 (31, 50, 53) /
BR484 57 G2 + (7) + (7) 1+ 0.000 0.014 0.014 2 (55, 73+78 CBC) /
BR494 58 G3 + (5) - (0) - 0.020 0.352 0.372 4 (40, 43, 45, NA M) /
BR498 46 G2 + (5) + (7) - 0.005 0.837 0.841 4 (42 BBC, 48, 49M, 74) /
BR506 55 G1 - (0) + (5) - 0.000 0.012 0.012 3 (62, 30, 76) /
BR535 56 G3 + (7) + (7) 1+ 0.000 0.019 0.019 3 (47, 53, NA) /
BR542 45 G3 + (7) + (7) 1+ 0.007 0.112 0.119 2 (36,62) /
BR545 63 G2 + (7) + (6) 1+ 0.000 0.003 0.003 2 (64, 70) /
BR549 36 G3 + (6) + (5) 1+ 0.013 0.142 0.155 1 (36) /
BR553 54 G2 + (7) + (6) 1+ 0.011 0.486 0.497 2 (49, 65) 1 (55)
BR558 45 G1 +(7) + (8) 1+ 0.000 0.029 0.030 3 (48, 78, 78) /
BR560 78 G2 + (7) + (3) 1+ 0.000 0.025 0.025 3 (45, 48, 78) /
BR569 41 G2 + (7) + (8) - 0.114 0.072 0.185 / 2 (60, 60)
BR582 27 G3 + (6) + (8) - 0.001 0.016 0.016 / /
BR584 42 / + (5) + (6) 1+ 0.001 0.017 0.018 3 (40, 54, 69) /
BR592 67 G2 +(7) +(7) 2+ 0.001 0.035 0.036 4 (48, 52, 55, 60) /
BR593 48 G3 +(7) + (3) 1+ 0.088 0.242 0.330 3 (33 BBC, 65, 70) 1 (24)
BR599 39+44 CBC G3 + (6) - (0) 3+ 0.187 0.370 0.557 2 (44, 60) /
BR603 40 G2 + (7) + (7) - 0.001 0.032 0.033 1 (36) /
BR615 49 G1 + (7) + (7) 1+ 0.000 0.004 0.004 2 (49, 50) /
BR649 80 G2 + (7) + (6) 1+ 0.001 0.404 0.406 2 (31, 44 BBC) /
BR650 47 G3 + (6) - (0) - 0.004 0.017 0.021 1 (45) /
BR656 43 G2 + (6) + (7) 1+ 0.003 0.269 0.272 3 (40, 44, 52) /
BR666 56 G2 + (8) + (6) 1+ 0.132 0.201 0.332 3 (39, 50, 51) 3 (49, 54, 61)
  1. BC = breast cancer; CBC = controlateral breast cancer; OC = ovarian cancer; / = no cases; M = male. The ages at diagnosis of the first cousins are in boldface type; ° IHC Allred total scores of 3 or more were reported as positive. §HER2 IHC scores: - negative, 1+ weak, 2+ moderate, 3+ strong. ^ Probability of mutation calculated by BRCAPRO software http://www.isds.duke.edu/~gp/brcapro.html; * number of additional tumours in the family and ages of onset in parentheses.